STX‐100 (BG00011): STX‐100 is an integrin αvβ6 mAb that partially inhibits TGF‐β and blocks murine pulmonary fibrosis without exacerbating inflammation.[529] Multiple phase II clinical trials have been conducted to evaluate the safety and efficacy of STX‐100 in IPF patients (NCT03573505, NCT01371305). The gene discussed is TGFB1; the disease is pulmonary fibrosis.